Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.45% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTMACROGENICS INC's latest supported as-filed period reports revenue of $32.8M, 47.6% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.45% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -124.11% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 47.62% · CORE
Level · gp.fundamentals.operating_margin
Raw value -42.19% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 118.12% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 6.01% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 47.6%; Operating margin moved 12308 bp higher; Operating income increased 62.3%.
3 evidence-backed componentsOperating income changed +62.3% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
MGNX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001125345-26-000059SEC ↗4Aug 20, 2026Period Aug 19, 20260001706903-26-000006SEC ↗4Aug 18, 2026Period Aug 17, 20260001588365-26-000007SEC ↗10-QAug 14, 2026Period Jun 30, 20260001125345-26-000056SEC ↗8-KAug 13, 2026Period Aug 13, 20260001125345-26-000054SEC ↗8-KJul 23, 2026Period Jul 23, 20260001125345-26-000050SEC ↗8-KJul 8, 2026Period Jul 1, 20260001125345-26-000047SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 19, 2026Filed Aug 20, 2026 | Peters Jeffrey StuartSenior VP, GC, and Secretary | Open Market SaleDirect | 31,105 | $4 | $129,086 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating margin changed +12308 basis points from the comparable as-filed period.
Revenue changed +47.6% from the comparable as-filed period.
SBC / revenue changed -1058 basis points from the comparable as-filed period.
Stock-based compensation changed -46.5% from the comparable as-filed period.
Net income changed +153.8% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change. This reverses 2 consecutive comparable moves in the opposite direction.
Cash & equivalents changed -12.8% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001125345-26-000045